APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

HIV Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global HIV Vaccines Market Outlook and Growth Opportunities 2026

Report ID 173998830420 December 2025194 pages

Choose your research edition.

Industry ResearchHIV Vaccines Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal HIV Vaccines Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal HIV Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HIV Vaccines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal HIV Vaccines Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global HIV Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for HIV Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for HIV Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for HIV Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the HIV Vaccines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the HIV Vaccines market include Sanofi, Glaxosmithkline, Paxvax, Janssen Global Services, Inovio Pharmaceuticals, Geovax, Genecure, Bionor Pharma and Argos Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global HIV Vaccines market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of HIV Vaccines and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents HIV Vaccines revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global HIV Vaccines market.

HIV Vaccines Segment by Company

Sanofi

Glaxosmithkline

Paxvax

Janssen Global Services

Inovio Pharmaceuticals

Geovax

Genecure

Bionor Pharma

Argos Therapeutics

HIV Vaccines Segment by Type

Phase I

Phase II

Phase III

HIV Vaccines Segment by Application

Research Institute

Others

HIV Vaccines Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global HIV Vaccines status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the HIV Vaccines key companies, revenue, market share, and recent developments.

3. To split the HIV Vaccines breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions HIV Vaccines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify HIV Vaccines significant trends, drivers, influence factors in global and regions.

6. To analyze HIV Vaccines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HIV Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HIV Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HIV Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HIV Vaccines industry.

Chapter 3: Detailed analysis of HIV Vaccines company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of HIV Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of HIV Vaccines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. HIV Vaccines Industry Trends Table 2. HIV Vaccines Industry Drivers Table 3. HIV Vaccines Industry Opportunities and Challenges Table 4. HIV Vaccines Industry Restraints Table 5. Global HIV Vaccines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global HIV Vaccines Revenue Share by Company (2021-2026) Table 7. Global HIV Vaccines Company Ranking, (2024-2026) & (US$ Million) Table 8. Global HIV Vaccines Key Company Manufacturing Base & Headquarters Table 9. Global HIV Vaccines Company, Product Type & Application Table 10. Global HIV Vaccines Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global HIV Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Phase I Table 15. Significant Companies of Phase II Table 16. Significant Companies of Phase III Table 17. Global HIV Vaccines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global HIV Vaccines Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global HIV Vaccines Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global HIV Vaccines Sales Value Share by Type (2021-2026) Table 21. Global HIV Vaccines Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Research Institute Table 23. Significant Companies of Others Table 24. Global HIV Vaccines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global HIV Vaccines Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global HIV Vaccines Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global HIV Vaccines Sales Value Share by Application (2021-2026) Table 28. Global HIV Vaccines Sales Value Share by Application (2027-2032) Table 29. Global HIV Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global HIV Vaccines Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global HIV Vaccines Sales Value Share by Region (2021-2026) Table 32. Global HIV Vaccines Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global HIV Vaccines Sales Value Share by Region (2027-2032) Table 34. Global HIV Vaccines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global HIV Vaccines Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global HIV Vaccines Sales Value Market Share by Country (2021-2026) Table 37. Global HIV Vaccines Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global HIV Vaccines Sales Value Market Share by Country (2027-2032) Table 39. Sanofi Company Information Table 40. Sanofi Business Overview Table 41. Sanofi HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Sanofi HIV Vaccines Product Portfolio Table 43. Sanofi Recent Development Table 44. Glaxosmithkline Company Information Table 45. Glaxosmithkline Business Overview Table 46. Glaxosmithkline HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Glaxosmithkline HIV Vaccines Product Portfolio Table 48. Glaxosmithkline Recent Development Table 49. Paxvax Company Information Table 50. Paxvax Business Overview Table 51. Paxvax HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Paxvax HIV Vaccines Product Portfolio Table 53. Paxvax Recent Development Table 54. Janssen Global Services Company Information Table 55. Janssen Global Services Business Overview Table 56. Janssen Global Services HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Janssen Global Services HIV Vaccines Product Portfolio Table 58. Janssen Global Services Recent Development Table 59. Inovio Pharmaceuticals Company Information Table 60. Inovio Pharmaceuticals Business Overview Table 61. Inovio Pharmaceuticals HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Inovio Pharmaceuticals HIV Vaccines Product Portfolio Table 63. Inovio Pharmaceuticals Recent Development Table 64. Geovax Company Information Table 65. Geovax Business Overview Table 66. Geovax HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Geovax HIV Vaccines Product Portfolio Table 68. Geovax Recent Development Table 69. Genecure Company Information Table 70. Genecure Business Overview Table 71. Genecure HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Genecure HIV Vaccines Product Portfolio Table 73. Genecure Recent Development Table 74. Bionor Pharma Company Information Table 75. Bionor Pharma Business Overview Table 76. Bionor Pharma HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Bionor Pharma HIV Vaccines Product Portfolio Table 78. Bionor Pharma Recent Development Table 79. Argos Therapeutics Company Information Table 80. Argos Therapeutics Business Overview Table 81. Argos Therapeutics HIV Vaccines Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Argos Therapeutics HIV Vaccines Product Portfolio Table 83. Argos Therapeutics Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. HIV Vaccines Product Image Figure 2. Global HIV Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HIV Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global HIV Vaccines Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Phase I Image Figure 8. Phase II Image Figure 9. Phase III Image Figure 10. Global HIV Vaccines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global HIV Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global HIV Vaccines Sales Value Share by Type (2021-2032) Figure 13. Research Institute Image Figure 14. Others Image Figure 15. Global HIV Vaccines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global HIV Vaccines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global HIV Vaccines Sales Value Share by Application (2021-2032) Figure 18. Global HIV Vaccines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global HIV Vaccines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America HIV Vaccines Sales Value (2021-2032) & (US$ Million) Figure 21. North America HIV Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe HIV Vaccines Sales Value (2021-2032) & (US$ Million) Figure 23. Europe HIV Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific HIV Vaccines Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific HIV Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America HIV Vaccines Sales Value (2021-2032) & (US$ Million) Figure 27. South America HIV Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa HIV Vaccines Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa HIV Vaccines Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt HIV Vaccines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt HIV Vaccines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt HIV Vaccines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Phase I
  • Phase II
  • Phase III
Applications
  • Research Institute
  • Others
Companies covered
  • Sanofi
  • Glaxosmithkline
  • Paxvax
  • Janssen Global Services
  • Inovio Pharmaceuticals
  • Geovax
  • Genecure
  • Bionor Pharma
  • Argos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global HIV Vaccines Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global HIV Vaccines Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 HIV Vaccines Market Dynamics
  1. 2.1 HIV Vaccines Industry Trends
  2. 2.2 HIV Vaccines Industry Drivers
  3. 2.3 HIV Vaccines Industry Opportunities and Challenges
  4. 2.4 HIV Vaccines Industry Restraints
3 HIV Vaccines Market by Company
  1. 3.1 Global HIV Vaccines Company Revenue Ranking in 2025
  2. 3.2 Global HIV Vaccines Revenue by Company (2021-2026)
  3. 3.3 Global HIV Vaccines Company Ranking (2024-2026)
  4. 3.4 Global HIV Vaccines Company Manufacturing Base and Headquarters
  5. 3.5 Global HIV Vaccines Company Product Type and Application
  6. 3.6 Global HIV Vaccines Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global HIV Vaccines Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 HIV Vaccines Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 HIV Vaccines Market by Type
  1. 4.1 HIV Vaccines Type Introduction
  2. 4.1.1 Phase I
  3. 4.1.2 Phase II
  4. 4.1.3 Phase III
  5. 4.2 Global HIV Vaccines Sales Value by Type
  6. 4.2.1 Global HIV Vaccines Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global HIV Vaccines Sales Value by Type (2021-2032)
  8. 4.2.3 Global HIV Vaccines Sales Value Share by Type (2021-2032)
5 HIV Vaccines Market by Application
  1. 5.1 HIV Vaccines Application Introduction
  2. 5.1.1 Research Institute
  3. 5.1.2 Others
  4. 5.2 Global HIV Vaccines Sales Value by Application
  5. 5.2.1 Global HIV Vaccines Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global HIV Vaccines Sales Value by Application (2021-2032)
  7. 5.2.3 Global HIV Vaccines Sales Value Share by Application (2021-2032)
6 HIV Vaccines Regional Value Analysis
  1. 6.1 Global HIV Vaccines Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global HIV Vaccines Sales Value by Region (2021-2032)
  3. 6.2.1 Global HIV Vaccines Sales Value by Region: 2021-2026
  4. 6.2.2 Global HIV Vaccines Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America HIV Vaccines Sales Value (2021-2032)
  7. 6.3.2 North America HIV Vaccines Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe HIV Vaccines Sales Value (2021-2032)
  10. 6.4.2 Europe HIV Vaccines Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific HIV Vaccines Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific HIV Vaccines Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America HIV Vaccines Sales Value (2021-2032)
  16. 6.6.2 South America HIV Vaccines Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa HIV Vaccines Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa HIV Vaccines Sales Value Share by Country, 2025 VS 2032
7 HIV Vaccines Country-level Value Analysis
  1. 7.1 Global HIV Vaccines Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global HIV Vaccines Sales Value by Country (2021-2032)
  3. 7.2.1 Global HIV Vaccines Sales Value by Country (2021-2026)
  4. 7.2.2 Global HIV Vaccines Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA HIV Vaccines Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada HIV Vaccines Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico HIV Vaccines Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany HIV Vaccines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France HIV Vaccines Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. HIV Vaccines Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy HIV Vaccines Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain HIV Vaccines Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia HIV Vaccines Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands HIV Vaccines Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries HIV Vaccines Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China HIV Vaccines Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan HIV Vaccines Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea HIV Vaccines Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India HIV Vaccines Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia HIV Vaccines Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia HIV Vaccines Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil HIV Vaccines Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina HIV Vaccines Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile HIV Vaccines Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia HIV Vaccines Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru HIV Vaccines Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia HIV Vaccines Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel HIV Vaccines Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE HIV Vaccines Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey HIV Vaccines Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran HIV Vaccines Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran HIV Vaccines Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt HIV Vaccines Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt HIV Vaccines Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt HIV Vaccines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi HIV Vaccines Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi HIV Vaccines Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 Glaxosmithkline
  8. 8.2.1 Glaxosmithkline Company Information
  9. 8.2.2 Glaxosmithkline Business Overview
  10. 8.2.3 Glaxosmithkline HIV Vaccines Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Glaxosmithkline HIV Vaccines Product Portfolio
  12. 8.2.5 Glaxosmithkline Recent Developments
  13. 8.3 Paxvax
  14. 8.3.1 Paxvax Company Information
  15. 8.3.2 Paxvax Business Overview
  16. 8.3.3 Paxvax HIV Vaccines Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Paxvax HIV Vaccines Product Portfolio
  18. 8.3.5 Paxvax Recent Developments
  19. 8.4 Janssen Global Services
  20. 8.4.1 Janssen Global Services Company Information
  21. 8.4.2 Janssen Global Services Business Overview
  22. 8.4.3 Janssen Global Services HIV Vaccines Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Janssen Global Services HIV Vaccines Product Portfolio
  24. 8.4.5 Janssen Global Services Recent Developments
  25. 8.5 Inovio Pharmaceuticals
  26. 8.5.1 Inovio Pharmaceuticals Company Information
  27. 8.5.2 Inovio Pharmaceuticals Business Overview
  28. 8.5.3 Inovio Pharmaceuticals HIV Vaccines Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Inovio Pharmaceuticals HIV Vaccines Product Portfolio
  30. 8.5.5 Inovio Pharmaceuticals Recent Developments
  31. 8.6 Geovax
  32. 8.6.1 Geovax Company Information
  33. 8.6.2 Geovax Business Overview
  34. 8.6.3 Geovax HIV Vaccines Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Geovax HIV Vaccines Product Portfolio
  36. 8.6.5 Geovax Recent Developments
  37. 8.7 Genecure
  38. 8.7.1 Genecure Company Information
  39. 8.7.2 Genecure Business Overview
  40. 8.7.3 Genecure HIV Vaccines Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genecure HIV Vaccines Product Portfolio
  42. 8.7.5 Genecure Recent Developments
  43. 8.8 Bionor Pharma
  44. 8.8.1 Bionor Pharma Company Information
  45. 8.8.2 Bionor Pharma Business Overview
  46. 8.8.3 Bionor Pharma HIV Vaccines Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bionor Pharma HIV Vaccines Product Portfolio
  48. 8.8.5 Bionor Pharma Recent Developments
  49. 8.9 Argos Therapeutics
  50. 8.9.1 Argos Therapeutics Company Information
  51. 8.9.2 Argos Therapeutics Business Overview
  52. 8.9.3 Argos Therapeutics HIV Vaccines Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Argos Therapeutics HIV Vaccines Product Portfolio
  54. 8.9.5 Argos Therapeutics Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst